Finally, we show that the inhibition of ERCC1/XPF by the EGCGprodrug, Pro-EGCG (EGCG octaacetate), could significantly enhance response to cisplatin in tumor xenografts in vivo by increasing tumor cell death and decreasing proliferation. Here, ERCC4 is linked to neoplasm.